Anhui Anke Biotechnology (SHE:300009) received approval from the Chinese drug administration to conduct clinical trials into a growth hormone drug, according to a Shenzhen Stock Exchange filing on Thursday.
The injection will be tested in babies considered small-for-gestational-age (SGA), a disease that affects infants' growth and development, the biotech company said.
The company's shares closed 3% higher on Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。